1. Introduction {#sec1-cancers-11-00390}
===============

The majority of cancer patients suffer from pain during course of their disease \[[@B1-cancers-11-00390]\]. Pain may be a result of a growing primary tumour, metastases in lymph nodes, but predominately it occurs in patients experiencing distant metastases, particularly to the skeletal system. Pain management can significantly improve patients' quality of life \[[@B2-cancers-11-00390]\]. Antineoplastic treatment, e.g., radiation therapy, may also cause transient pain, which has to be managed pharmacologically \[[@B3-cancers-11-00390]\]. Radiation therapy (RT) per se, however, significantly contributes to pain alleviation in cancer patients in multiple clinical scenarios \[[@B4-cancers-11-00390],[@B5-cancers-11-00390]\]. Pain relief after radiation therapy may be achieved in as many as 60--80% of patients \[[@B2-cancers-11-00390]\]. Recently, a strong need of substantial engagement of radiation oncologists in pain relief (among other symptoms produced by advanced disease) in cancer patients was a subject of the American Society for Radiation Oncology (ASTRO) members' statement \[[@B6-cancers-11-00390]\].

2. Painful Bone Metastases {#sec2-cancers-11-00390}
==========================

About 50% of all cancer patients will develop bone metastases \[[@B7-cancers-11-00390]\]. The frequency of bone metastases' occurrence depends on tumour type, with breast, prostate, and lung cancers accounting for 85% of the cases \[[@B8-cancers-11-00390],[@B9-cancers-11-00390]\]. Other primaries which frequently produce bone metastases include urinary bladder, renal, endometrial, and thyroid cancer as well as melanoma \[[@B9-cancers-11-00390]\]. Bone pain may be caused by a local invasion of a metastatic tumour, which leads to remodelling of the microenvironment (changing the equilibrium between the activity of osteoblasts and osteoclast and bone structural degradation), direct nerve root invasion, or an increased release of inflammatory mediators, which stimulate nerve fibres \[[@B10-cancers-11-00390],[@B11-cancers-11-00390],[@B12-cancers-11-00390]\]. Furthermore, a spasm of surrounding muscles may cause discomfort to the patient. Radiotherapy is the most effective treatment for bone metastases \[[@B13-cancers-11-00390]\].

2.1. Pathomechanism of Analgesic Effect of Radiation {#sec2dot1-cancers-11-00390}
----------------------------------------------------

The exact mechanism of radiation-induced pain relief is unknown. The analgesic effect of radiation is achieved by stimulating ossification, diminishing osteoclasts' activity in bone microenvironment, and killing cancer cells along with reduced osteolysis, which results in decreasing tumour burden \[[@B12-cancers-11-00390],[@B14-cancers-11-00390]\]. Rapid pain relief (even after 24 h), observed in some patients, indicates a decrease of inflammatory cell activity as well as chemical pain mediators concentration in the radiation field, which play a role in the analgesic effect of radiation \[[@B15-cancers-11-00390]\]. The RT fractionation scheme in patients with bone metastasis influences the level of mineralization, bone density, and recalcification of the irradiated site \[[@B16-cancers-11-00390],[@B17-cancers-11-00390]\], which is associated with pain response. The recalcification rate was lower in the single fraction group (120%) compared to patients who received fractionated RT (173%, *p* \< 0.0001) with a slight trend favouring 10 × 3 Gy RT scheme \[[@B17-cancers-11-00390]\]. An association was observed between radiotherapy-driven bone pain relief and low osteoclast activity markers' (pyridinoline---PYD, and deoxypyridinoline---DPD) concentrations in the urine before and after RT \[[@B18-cancers-11-00390]\]. Re-irradiation for painful bone metastases also influences osteoclast activity visualized by urinary markers---PYD and DPD \[[@B19-cancers-11-00390]\]. Significant differences at the baseline markers' urinary levels were detected between 40 responders and 69 non-responders to re-irradiation (*p* = 0.03 for PYD and *p* = 0.04 for DPD) \[[@B19-cancers-11-00390]\].

2.2. External Beam Radiation Therapy for Painful Bone Metastases {#sec2dot2-cancers-11-00390}
----------------------------------------------------------------

Radiation therapy with external beams may be delivered using different radiation techniques, the most common of which, for the purpose of irradiation of painful bone metastases, are the following: Two-dimensional radiation therapy (2D-RT) ([Figure 1](#cancers-11-00390-f001){ref-type="fig"}), still used especially in patients with expected short survival, and three-dimensional conformal radiation therapy (3D-CRT) ([Figure 2](#cancers-11-00390-f002){ref-type="fig"}). Modern modifications of the 3D-CRT radiation techniques include intensity modulated radiation therapy (IMRT), volumetrically modulated arch therapy (VMAT), or tomotherapy \[[@B20-cancers-11-00390]\], which allow for better tumour coverage along with sparing surrounding normal tissue, thus decreasing potential toxicity of the treatment ([Figure 2](#cancers-11-00390-f002){ref-type="fig"}). Nowadays, sophisticated stereotactic radiosurgery (SRS) or stereotactic body radiation therapy (SBRT), allowing for delivery of a very high biological dose of radiation for very precisely delineated tumour masses, is increasingly used in selected groups of patients ([Figure 2](#cancers-11-00390-f002){ref-type="fig"}). Qualification of a particular patient for certain techniques and fractionation schedules in clinical practice depends on multiple factors ([Table 1](#cancers-11-00390-t001){ref-type="table"}).

### 2.2.1. Conformal Radiation Therapy {#sec2dot2dot1-cancers-11-00390}

The optimal choice of fractionation schedule for the treatment of painful bone metastases is still an unresolved issue. Most skeletal metastases are multiple in nature and only 10% are diagnosed as solitary ones \[[@B21-cancers-11-00390]\].

During the last three decades, many randomized and observational trials focused on the optimal choice of the dose and fractionation regimen for pain relief \[[@B9-cancers-11-00390],[@B17-cancers-11-00390],[@B22-cancers-11-00390],[@B23-cancers-11-00390],[@B24-cancers-11-00390],[@B25-cancers-11-00390],[@B26-cancers-11-00390],[@B27-cancers-11-00390],[@B28-cancers-11-00390]\]. They demonstrated an equivalent analgesic effect and durability of a single 8 Gray (Gy) fraction with multiple fractionation schedules, such as 30 Gy delivered in 10 fractions, 24 Gy given in 6 fractions, or 20 Gy in 5 fractions ([Table 2](#cancers-11-00390-t002){ref-type="table"}) \[[@B9-cancers-11-00390],[@B17-cancers-11-00390],[@B21-cancers-11-00390],[@B22-cancers-11-00390],[@B23-cancers-11-00390],[@B24-cancers-11-00390],[@B25-cancers-11-00390],[@B26-cancers-11-00390],[@B27-cancers-11-00390],[@B28-cancers-11-00390]\].

A meta-analysis of 25 randomized clinical trials revealed that up to 80% of patients with uncomplicated bone metastases experience analgesic response to external beam radiotherapy and 25--30% of patients achieve complete pain relief within 3--4 weeks after radiation therapy \[[@B2-cancers-11-00390]\]. Uncomplicated bone metastases include metastatic tumour masses without massive infiltration towards soft tissue, characterized by a low risk of imminent pathological fracture and no evidence of spinal cord compression or cauda equina compression, and which were not previously irradiated \[[@B15-cancers-11-00390]\]. Pain control persisting 3--6 months after radiation therapy, however, is experienced by 35% of patients only \[[@B2-cancers-11-00390]\]. Of note, the re-treatment rate to in-field pain recurrence was higher in those patients who received single-fraction regimens than in those treated with multiple fraction schemes (20% vs. 8%, *p* \< 0.00001) \[[@B2-cancers-11-00390]\]. Yet, it is unclear if this was due to lower durability of pain control or to the physician's comfort with re-treating after a lower initial radiation dose. It should be emphasized that single fraction treatment was associated with lower acute toxicity (nausea and vomiting, diarrhoea, fatigue, or skin toxicity). On the other hand, single fraction treatment was related to a higher rate of spinal cord compression and pathological fractures, but the difference did not reach statistical significance. The limitation of this meta-analysis are nonuniform primary end-points in different studies \[[@B2-cancers-11-00390]\].

Despite the same efficacy of a single 8 Gy fraction, compared with multiple-fraction regimens and available published guidelines \[[@B11-cancers-11-00390],[@B15-cancers-11-00390]\], to date this single fraction schedule is underused in the clinical practice to treat painful bone metastases \[[@B33-cancers-11-00390]\]. Fischer-Valuck et al. \[[@B34-cancers-11-00390]\], however, report increased usage of short course radiation therapy (1 × 8 Gy or 5 × 4 Gy) over long course treatment in 2014, compared to 2000, particularly in academic centres, in elderly prostate cancer patients living more than 15 miles from the treatment facility. In fact, single radiation fraction treatment allows patients to receive the planning procedure and radiation therapy within the same day, which is of particular importance for those with poor performance status \[[@B35-cancers-11-00390],[@B36-cancers-11-00390]\].

The decision making should be based on treatment-related costs as well. In this context, some study results are of interest. A Dutch randomized controlled trial enrolling 1157 patients revealed that the cost of radiation therapy, including re-treatments and other nonmedical costs, was significantly lower for a single fraction regimen compared to a multiple fraction schedule (\$2438 vs. \$3311, *p* \< 0.001) \[[@B37-cancers-11-00390]\]. Similar financial results were obtained by the Radiation Therapy Oncology Group (RTOG, trial 9714) \[[@B38-cancers-11-00390]\]. The New Zealand study revealed that single fraction radiotherapy costs per patient amounted to NZ\$1344 and were lower than the costs of multiple fractionation regimens for prostate cancer patients \[[@B39-cancers-11-00390]\]. Furthermore, SEER (The Surveillance, Epidemiology and End Results) analysis found a difference of \$3094 between single fraction and multiple fractionations (10 fractions or more) \[[@B40-cancers-11-00390]\]. It has been estimated that an absolute increase of 10% of single fraction radiation therapy administration for painful bone metastases in prostate cancer patients' population could generate more than \$70 million per year in health cost savings \[[@B41-cancers-11-00390],[@B42-cancers-11-00390],[@B43-cancers-11-00390]\]. Of interest, in India the average distance travelled per day by a patient for radiation treatment is about 100 km \[[@B27-cancers-11-00390]\], which means that patients undergoing single fraction treatment will travel 100 km for a complete radiation regimen, whereas patients undergoing 10-fraction radiation therapy will travel approx. 1000 km. It increases the costs from Rs1010 to Rs9700 per patient \[[@B27-cancers-11-00390],[@B37-cancers-11-00390],[@B38-cancers-11-00390],[@B39-cancers-11-00390],[@B40-cancers-11-00390],[@B41-cancers-11-00390],[@B42-cancers-11-00390],[@B43-cancers-11-00390]\].

The neuropathic pain component represents a special issue. It occurs in 19--39% of cancer patients \[[@B44-cancers-11-00390],[@B45-cancers-11-00390],[@B46-cancers-11-00390]\]. Pain management with pharmacotherapy may be troublesome, although it is the mainstay of the treatment \[[@B46-cancers-11-00390],[@B47-cancers-11-00390]\]. Of interest, in a prospective observational study, patients with tumour-related neuropathic pain components (93 out of 302 patients) were more likely to achieve a pain response after radiation therapy administration than those without such component \[[@B48-cancers-11-00390]\]. In this scenario, multifraction radiation therapy may be preferred to a single fraction, as it leads to longer durability of pain control \[[@B31-cancers-11-00390]\]. It is associated with a higher remineralization rate of irradiated vertebrae, in comparison to a single fraction \[[@B17-cancers-11-00390]\].

In case of spine metastases, combining percutaneous vertebroplasty (decreasing pain through restoring mechanical stability of vertebrae) with radiation therapy (exhibiting antitumor effect) provides better pain relief than radiotherapy alone \[[@B49-cancers-11-00390]\] ([Figure 3](#cancers-11-00390-f003){ref-type="fig"}).

In a scenario of spinal cord or cauda equina compression caused by a metastatic mass, direct decompressive surgery followed by radiation therapy seems to be superior to radiotherapy alone \[[@B50-cancers-11-00390]\]. The usual dose is 20 Gy delivered in 5 days or 30 Gy given in 10 days \[[@B15-cancers-11-00390]\]. In patients who are unfit for surgical management, radiation therapy is indicated to alleviate the pain and decrease neurologic complications \[[@B15-cancers-11-00390]\], although the optimal dose and radiation regimen are not established yet. Taking into account medical emergency in spinal cord compression, a shorter radiation schedule is desirable. Results of a randomized controlled trial, performed in a group of 276 patients with life expectancies of fewer than 6 months, indicate that both regimens (8 Gy × 2 days and multifraction split regimen: 5 × 3 Gy and 5 Gy × 3) are equally efficient (pain relief in 56% vs. 59% patients, motor capacity in 68% vs. 71% patients), thus the short course should be recommended as the treatment of choice in the group of patients \[[@B51-cancers-11-00390]\]. In patients with bone fractures, surgical management along with radiation therapy should be performed ([Figure 2](#cancers-11-00390-f002){ref-type="fig"}).

It should also be depicted that the histology of a metastatic tumour influences its radiosensitivity and the analgesic effect of radiation therapy. Arcangeli et al. \[[@B52-cancers-11-00390]\] demonstrated that non-small cell lung cancer metastases appeared to be the least responsive among all primary tumours, with 46% complete pain relief in comparison to bone metastases from breast and prostate cancers (65%, *p* = 0.04 and 83%, *p*-0.002, respectively).

In summary, the decision on RT fractionation should be supported by the American Society for Radiation Oncology (ASTRO) Evidence-Based Guideline \[[@B53-cancers-11-00390]\]. The panel states there exists pain equivalency following a single 8 Gy fraction, 20 Gy in 5 fractions, 24 Gy in 6 fractions, and 30 Gy in 10 fractions for patients with previously unirradiated painful bone metastases. Patients should be made aware that single fraction RT is associated with a higher rate of re-treatment to the same painful site than in fractionated treatment. A single fraction treatment may be particularly convenient and sensible for patients with limited life expectancy. Patients who experience persistent or recurrent pain more than one month following external beam radiation therapy (EBRT) for symptomatic peripheral bone metastases or in spine lesions should be considered for re-treatment while adhering to normal tissue dosing constraints described in the available literature \[[@B53-cancers-11-00390]\].

### 2.2.2. Hemibody Irradiation (HBI) {#sec2dot2dot2-cancers-11-00390}

In patients with multiple painful bone metastases, hemibody irradiation using external beams may be a treatment option. The upper, middle or, lower half of the skeleton may be irradiated. Both photon beams and electron beams may be used \[[@B54-cancers-11-00390],[@B55-cancers-11-00390]\]. Delivering 6--8 Gy in single fraction results in pain response in 70% of patients after 24--48 h \[[@B54-cancers-11-00390]\]. The intensity of pain is reduced significantly, from 8 to 1, according to the visual-analogue scale, and there is a decrease in morphine consumption \[[@B54-cancers-11-00390],[@B55-cancers-11-00390]\]. It is a very convenient treatment type for advanced cancer patients since it involves a short hospital stay and acceptable side effects \[[@B54-cancers-11-00390]\].

### 2.2.3. Stereotactic Surgery/Stereotactic Body Radiation Therapy {#sec2dot2dot3-cancers-11-00390}

As was mentioned earlier, since conventionally delivered radiation therapy leads to pain relief in approximately 80% of patients, but complete pain alleviation is only experienced by 25--30% of them, another concept of radiation therapy has emerged. Furthermore, the oligometastatic state in clinical practice has been defined when 1--5 distant metastases are found in a cancer patient \[[@B56-cancers-11-00390]\]. Advances in radiation therapy planning software, custom patients immobilization, and sophisticated radiation delivery equipment utilizing multiple conformal beams or arc therapy with intensity modulation and image guidance, with each treatment allowing for accuracy within millimetres, facilitate obtaining a very precisely covered radiation target with extremely high biological doses of radiation delivered in 1 to few fractions \[[@B57-cancers-11-00390]\] ([Figure 2](#cancers-11-00390-f002){ref-type="fig"}C). Single fraction radiation therapy is called "radiosurgery" whereas delivering multiple fractions---stereotactic body radiation therapy (SBRT). The latter is alternatively called stereotactic ablative radiotherapy since a huge biological dose of radiation is delivered to the treated target. Indications for SBRT include one to three vertebral metastases, less than 5 cm in diameter \[[@B52-cancers-11-00390]\]. Symptomatic spinal cord compression may be a contraindication for the treatment, as the myelopathy after SBRT may increase \[[@B57-cancers-11-00390]\]. Several doses per fraction are used, from single 15--24 Gy fractions to 18--36 Gy delivered in 1--5 fractions \[[@B57-cancers-11-00390],[@B58-cancers-11-00390],[@B59-cancers-11-00390],[@B60-cancers-11-00390],[@B61-cancers-11-00390],[@B62-cancers-11-00390]\]. Of note, data concerning efficacy and safety of the treatment come from retrospective analyses \[[@B46-cancers-11-00390],[@B47-cancers-11-00390],[@B48-cancers-11-00390],[@B49-cancers-11-00390],[@B50-cancers-11-00390],[@B51-cancers-11-00390]\]. Nevertheless, SRS/SBRT is widely used in most radiation therapy centres. About 40% of radiation oncologists in the US report that they use spine SBRT in their radiation departments and the single fraction is preferable due to greatest patient comfort and outpatient treatment convenience \[[@B63-cancers-11-00390]\]. Unfortunately, many studies assessing the efficacy of spine SBRT report excellent local control (LC approximately 90%), while they do not provide information on pain control \[[@B57-cancers-11-00390]\].

Most studies report that pain control continues for 1-year after spine SBRT in as many as 84--90% of patients \[[@B58-cancers-11-00390],[@B59-cancers-11-00390],[@B60-cancers-11-00390],[@B61-cancers-11-00390],[@B62-cancers-11-00390],[@B64-cancers-11-00390]\] and about 50% of patients experience complete pain relief at 6 months \[[@B61-cancers-11-00390],[@B65-cancers-11-00390]\].

To date, the optimal dose and fractionation schedule of SRS/SBRT is unclear. Chang et al. \[[@B58-cancers-11-00390]\] reported pain control in 89.2% of patients suffering from different types of tumours. Ryu et al. \[[@B59-cancers-11-00390]\], in a phase II dose escalation trial, demonstrated that a dose above 14 Gy in a single fraction was associated with increased pain control (one-year actuarial pain control was 84%, whereas 46% of patients experienced complete pain relief, 18.9%---partial relief, and 16.2% reported stable pain intensity). Currently, a RTOG 0631 phase 2/3 randomized study compares pain relief between 8 Gy in a single fraction given with conventional radiotherapy versus 16 Gy in a single fraction delivered with stereotactic techniques \[[@B66-cancers-11-00390]\]. Sprave et al. \[[@B60-cancers-11-00390]\], in a single-institution randomized explorative trial on a group of 55 patients suffering from painful spinal metastases, documented that after single-fraction SRS (24 Gy), patients achieved quicker and improved pain responses, in comparison to 3DCRT (30 Gy in 10 fractions). McGee et al. \[[@B67-cancers-11-00390]\], in a retrospective analysis of 96 patients undergoing SRS to the spine metastases from primary tumours of radioresistant histology (hepatocellular cancer, cholangiocarcinoma, renal cell carcinoma, melanoma, or leiomyosarcoma), found high rates of pain relief (93%), but pointed out that hepatocellular carcinoma was associated with an inferior response to radiation therapy. The concept of single fraction SRS has some limitations. The most important one is the risk of postradiation myelopathy since vertebral masses are in close proximity to the spinal cord, which is characterized by a limited dose of tolerance \[[@B62-cancers-11-00390],[@B68-cancers-11-00390]\]. In cases of radiosurgical treatment, the epidural tumour component is the most frequent site of treatment failure, since the spine and epidural tumour mass was spared from a high dose of radiation \[[@B58-cancers-11-00390],[@B59-cancers-11-00390],[@B60-cancers-11-00390],[@B62-cancers-11-00390],[@B66-cancers-11-00390],[@B67-cancers-11-00390],[@B68-cancers-11-00390]\]. Thus, a distance of more than 3 mm from the tumour mass and spinal cord is desired \[[@B66-cancers-11-00390]\].

Fractionated SBRT to spine metastases (27 Gy in 3 fractions) resulted in pain relief in 52% of renal cancer patients after one year \[[@B61-cancers-11-00390]\]. An 84% improvement in symptomatic patients was also observed in a study performed by Gibbs et al. \[[@B62-cancers-11-00390]\]. In a retrospective, international, and multicentre study based on 387 spinal metastases treated with SBRT (median total dose---24 Gy in 3 fractions) it was demonstrated that worse outcomes of radiation therapy were associated with an interval between primary tumour diagnosis and SBRT smaller than 30 months and the presence of histology of primary cancer, such as non-small cell lung cancer, renal cell cancer, and/or melanoma \[[@B69-cancers-11-00390]\]. Prior to the treatment, patients were pain-free or reported pain of mild/moderate or severe intensity in 18.2%, 64.9%, and 16.9%, respectively. The patients remained pain-free at the time of the last clinical assessment (median follow-up of 11.5 months) in 76.8%, 56.3%, and 43.8%, respectively \[[@B64-cancers-11-00390],[@B69-cancers-11-00390]\]. According to ASTRO guidelines, advanced radiation techniques, such as SBRT as the primary treatment for painful spine bone lesions, should be considered in the setting of a clinical trial or with data collected in a registry, given that insufficient data is available to routinely use this treatment \[[@B53-cancers-11-00390]\].

### 2.2.4. Re-Irradiation {#sec2dot2dot4-cancers-11-00390}

Palliative radiation therapy of bone metastasis for recurrent pain after previous palliative radiotherapy may be administered. It depends, however, on the location, prior radiation dose, fractionation schedule, and the time between radiation treatments \[[@B70-cancers-11-00390]\]. Results obtained by Chow et al. \[[@B36-cancers-11-00390]\], in a randomized trial, demonstrated that retreatment with a single fraction for painful bone metastases produces an effect equal to a multifraction conventional radiation therapy. The second conventional radiation treatment should be given no earlier than after 1 month \[[@B36-cancers-11-00390]\]. Response to re-irradiation with conventional radiation therapy, however, was modest, with overall response rates of 45--52% and complete pain relief experienced by only 11--14% of patients \[[@B36-cancers-11-00390]\]. These indicate a need for more effective re-treatment, and SBRT offers such opportunity \[[@B71-cancers-11-00390],[@B72-cancers-11-00390]\]. A systematic review of studies concerning SBRT in re-irradiation of spine masses proved safety and good results in terms of local control and pain relief, although data is of low-quality or limited \[[@B72-cancers-11-00390]\]. Only some studies reported results concerning pain control \[[@B58-cancers-11-00390],[@B73-cancers-11-00390],[@B74-cancers-11-00390],[@B75-cancers-11-00390],[@B76-cancers-11-00390],[@B77-cancers-11-00390]\]. ([Table 3](#cancers-11-00390-t003){ref-type="table"}).

In the case of previously irradiated, but progressing spinal metastases, re-irradiation should be ordered with caution, since the spinal cord is a radiosensitive structure \[[@B78-cancers-11-00390],[@B79-cancers-11-00390]\]. The risk of myelopathy after re-irradiation is presumably low if the following conditions are met: The cumulative dose is less 135.5 Gy~2~, the interval between treatments is more than 6 months, and no course of radiation therapy exceeds the dose of 98 Gy~2~ \[[@B70-cancers-11-00390],[@B80-cancers-11-00390]\] Sahgal et al. \[[@B64-cancers-11-00390]\] found that an interval between conventional palliative radiation therapy and SBRT re-irradiation longer than 5 months, when maximum point dose to the thecal sac is limited to nBED 20--25 Gy (2/2), appears to be safe. Furthermore, the cumulative point max to the thecal sac should not exceed 70 Gy (2/2) and the SBRT thecal sac point max dose should not be above 50% of the total cumulative dose \[[@B64-cancers-11-00390]\]. According to ASTRO guidelines, advanced radiation techniques, such as SBRT re-treatment for recurrent pain in spine bone lesions, may be feasible, effective, and safe, but this approach should be limited to clinical trial participation or on a registry given limited data supporting routine use \[[@B53-cancers-11-00390]\].

This review is concentrated on radiation influence on pain control in cancer patients, but one has to realise that the final decision on qualification of patients to the SRS/SBRT should be taken at a multidisciplinary tumour board, assisted by the oncologic, neurologic, mechanical, and systemic framework defined by Laufer et al. \[[@B81-cancers-11-00390]\], which allows for personalization of therapy.

3. Brachytherapy for the Treatment of Painful Bone Metastases {#sec3-cancers-11-00390}
=============================================================

Brachytherapy consists in the application of radioactive sources inside the patient's body (directly to the tumour burden or to the postoperative tumour bed) temporarily or permanently, which is meant to damage cancer cells' DNA and destroy their ability to divide and grow. It allows for the use of a higher total dose of radiation to treat a smaller area in less time than the conventional external beam radiation therapy. Brachytherapy is a rarely used treatment option for bone metastases. Recently, a systematic review was published, which summarized the role of the treatment modality in painful spinal metastases \[[@B82-cancers-11-00390]\]. Seven studies (which analysed treatment efficacy on pain control) reported a decrease of pain intensity after brachytherapy \[[@B83-cancers-11-00390],[@B84-cancers-11-00390],[@B85-cancers-11-00390],[@B86-cancers-11-00390],[@B87-cancers-11-00390],[@B88-cancers-11-00390],[@B89-cancers-11-00390]\] ([Table 4](#cancers-11-00390-t004){ref-type="table"}).

Pain Flare Syndrome
-------------------

Pain relief contributes to improved quality of life of cancer patients, which is currently one of the most important goals of the treatment. Radiation therapy is widely used for decreasing pain in the population, however, in some patients "pain flare" can occur after this treatment. It is observed in 2--40% of patients \[[@B90-cancers-11-00390],[@B91-cancers-11-00390]\] and is defined as a temporary increase of bone pain at the treated site during radiation therapy or early after its cessation \[[@B92-cancers-11-00390]\]. Although the precise mechanism of this phenomenon is not recognized yet, biochemical mediators of inflammation, which are released upon the radiation therapy or transient oedema compressing nerves at the site of treatment, are suggested to contribute to this toxicity \[[@B93-cancers-11-00390]\]. Steroids decrease pain flare intensity \[[@B28-cancers-11-00390]\]. Furthermore, anti-inflammatory medications may prevent or reduce the risk of toxicity.

4. Radioactive Isotopes for the Treatment of Painful Bone Metastases {#sec4-cancers-11-00390}
====================================================================

In cancer patients suffering from multiple bone metastases, bone-seeking radiopharmaceuticals have proven to be an effective alternative \[[@B94-cancers-11-00390],[@B95-cancers-11-00390],[@B96-cancers-11-00390],[@B97-cancers-11-00390],[@B98-cancers-11-00390]\] ([Figure 4](#cancers-11-00390-f004){ref-type="fig"}, [Table 5](#cancers-11-00390-t005){ref-type="table"}). Strontium-89 chloride, Samarium-153-ethylenediamine tetramethylene phosphonic acid (EDTMP), Rhenium-186-hydroxyethylidine diphosphonic acid (HEDP), and Radium-233 dichloride have been approved for the treatment of bone pain due to osteoblastic or mixed bone metastases, mainly from prostate and breast cancers (most common indications) and other tumours presenting with painful osteoblastic lesions, confirmed by whole-body bone scintigraphy performed within at least 8 weeks before therapy \[[@B98-cancers-11-00390],[@B99-cancers-11-00390],[@B100-cancers-11-00390],[@B101-cancers-11-00390]\]. These agents mainly accumulate in osteosclerotic and osteoblastic bone metastases, whereas they are not suitable for treating osteolytic and osteoclastic bone metastases. Furthermore, in metastatic bones vulnerable to fracture, local therapy such as surgery or radiation therapy should be performed prior to radionuclide therapy \[[@B102-cancers-11-00390]\].

The mechanism of pain palliation resulting from beta particles or alpha particles emitted by radionuclides is not clear yet. Beta or alpha particles kill tumour cells; therefore, pain relief occurs because of mechanical pressure reduction ([Figure 5](#cancers-11-00390-f005){ref-type="fig"}). Pain control, however, frequently occurs before the tumour mass shrinks. Lymphocytes, which are radiation sensitive cells, secrete a variety of cytokines causing pain. The death of lymphocytes cells at the tumour site may also contribute to pain relief \[[@B94-cancers-11-00390]\].

4.1. Several Radionuclides Are Used in Clinical Practice, and Many of Them Are under Investigation {#sec4dot1-cancers-11-00390}
--------------------------------------------------------------------------------------------------

### 4.1.1. Strontium-89 Chloride {#sec4dot1dot1-cancers-11-00390}

There is solid data on the efficacy of Strontium-89 Chloride for bone pain relief in patients with prostate and breast cancers, with a pain relief rate of 63--88% \[[@B94-cancers-11-00390],[@B103-cancers-11-00390],[@B104-cancers-11-00390],[@B105-cancers-11-00390],[@B106-cancers-11-00390],[@B107-cancers-11-00390],[@B108-cancers-11-00390],[@B109-cancers-11-00390],[@B110-cancers-11-00390]\]. Symptomatic improvement usually occurred within 6 weeks after administration, with a mean duration of the pain-free period of about 6 months \[[@B111-cancers-11-00390]\], with no dose-response relationship \[[@B112-cancers-11-00390]\]. Retreatment for responders is possible at time intervals of not less than 12 weeks \[[@B112-cancers-11-00390],[@B113-cancers-11-00390]\].

### 4.1.2. Samarium-153-EDTMP {#sec4dot1dot2-cancers-11-00390}

Reduction of bone pain occurs in 62--78% of patients with bone metastases within 1 week of Samarium-153-EDTMP administration, with a definite dose-response relationship \[[@B109-cancers-11-00390],[@B114-cancers-11-00390],[@B115-cancers-11-00390],[@B116-cancers-11-00390],[@B117-cancers-11-00390],[@B118-cancers-11-00390],[@B119-cancers-11-00390],[@B120-cancers-11-00390],[@B121-cancers-11-00390]\], with a mean duration of approximately 3--8 months. In several phase II/III clinical trials this radionuclide has shown significant efficacy for bone pain alteration in patients with various types of cancer, including lung, prostate, and breast cancer as well as osteosarcoma \[[@B122-cancers-11-00390],[@B123-cancers-11-00390],[@B124-cancers-11-00390]\]. The minimum interval for retreatment should be 8 weeks \[[@B112-cancers-11-00390],[@B113-cancers-11-00390]\].

### 4.1.3. Radium-223-Dichloride {#sec4dot1dot3-cancers-11-00390}

A phase III randomized double-blind placebo-controlled trial, ALSYMPCA, investigated the effectiveness of Radium-223-dichloride in 921 patients with metastatic castration-resistant prostate cancer with symptomatic bone metastases, previous use of analgesics or radiotherapy to bones, and no visceral metastasis. There was a significant improvement in median overall survival in the Radium-223-dichloride group vs. the placebo group (14.9 vs. 11.3 months respectively) and median time to the first symptomatic skeletal event (15.6 vs. 9.8 months, respectively) \[[@B125-cancers-11-00390],[@B126-cancers-11-00390],[@B127-cancers-11-00390]\]. Median time to initial opioid use was significantly longer in the Ra-223 group, with risk reduction of 38%, compared to placebo. Less Ra-223 patients (36%) than placebo patients (50%) required opioids for pain relief. The QOL pain score showed reduced pain for Ra-223 patients relative to placebo patients at week 16 \[[@B128-cancers-11-00390]\].

### 4.1.4. Rhenium-186-HEDP {#sec4dot1dot4-cancers-11-00390}

Clinical studies assessing Rhenium-186-HEDP were mainly performed on patients with prostate cancer and breast cancer \[[@B129-cancers-11-00390],[@B130-cancers-11-00390],[@B131-cancers-11-00390],[@B132-cancers-11-00390],[@B133-cancers-11-00390]\]. General response rates for pain palliation ranged between 38% and 82% \[[@B95-cancers-11-00390],[@B99-cancers-11-00390],[@B134-cancers-11-00390],[@B135-cancers-11-00390],[@B136-cancers-11-00390],[@B137-cancers-11-00390],[@B138-cancers-11-00390],[@B139-cancers-11-00390]\]. A pain response occurred 1--3 weeks after administration, with a durability of 5--12 months. No definite relationship between dose and pain response was observed \[[@B138-cancers-11-00390]\]. Retreatment for responders is possible at time intervals of not less 6--8 weeks \[[@B140-cancers-11-00390],[@B141-cancers-11-00390]\].

### 4.1.5. Rhenium-188-HEDP {#sec4dot1dot5-cancers-11-00390}

In a study by Palmedo et al. \[[@B142-cancers-11-00390]\], with Rhenium-188-HEDP pain relief occurred in 64% of prostate cancer patients with bone metastases. Mean duration of the effect was 7.5 weeks \[[@B142-cancers-11-00390]\]. In a study by Liepe et al. \[[@B143-cancers-11-00390]\], pain relief was achieved in 76% of patients with hormone-refractory prostate carcinoma treated with the radionuclide. Therefore, in patients with progressive hormone-resistant prostate carcinoma and bone pain, repeated Rhenium-188-HEDP administration revealed the pain response rate of 92% vs. 60% and durability of response of 5.66 months, compared to 2.55 months for the single treatment group, respectively \[[@B144-cancers-11-00390]\].

4.2. Side Effects of Radionuclide Therapy {#sec4dot2-cancers-11-00390}
-----------------------------------------

The above-mentioned agents may produce some side effects such as gastrointestinal ulceration, enhanced bleeding, neutropenia, and disturbed renal function \[[@B94-cancers-11-00390]\]. In about 10% of cases, regardless of the agent used, there is a possibility of a flare (a painful response with an increase of pain insensitivity). Usually, within 72 h of administration, these symptoms (typically temporary, mild, and self-limiting) should be gone. When osseous metastases involve the cervical spine, a low risk of post-therapy spinal cord compression exists and prophylactic corticosteroids should be given \[[@B97-cancers-11-00390],[@B98-cancers-11-00390],[@B99-cancers-11-00390]\].

5. Radiation Therapy for Painful Primary/Regional/Metastatic Solid Tumours Other Than Bone Tumours {#sec5-cancers-11-00390}
==================================================================================================

Progressing soft tissue tumours may also produce mild to severe pain. Primary or metastatic brain tumours, particularly those presenting with a larger mass effect or surrounding oedema, are frequently associated with pain. Surgery and radiotherapy are under consideration in the group of patients, depending on different factors (performance status of the patient, presence of uncontrolled extracranial disease, expected survival, etc.). Brain radiation therapy, among others---whole brain radiation therapy---may help reduce tumour mass and volume of oedema, thus leading to pain relief. Lung cancer patients may suffer from severe pain resulting from the invasion of brachial plexus by the direct apical tumour. Meta-analysis of 14 randomized clinical trials evaluating palliative radiation therapy for lung cancer patients revealed satisfactory symptomatic relief, among others---pain reduction \[[@B150-cancers-11-00390]\]. Various fractionation schedules were used in the trials as follows: 10 Gy in 1 fraction, 17 Gy in 2 fractions, and 20 Gy in 5 fractions, as well as long courses, such as 30--45 Gy in 10--15 fractions \[[@B150-cancers-11-00390]\]. Locally advanced gastrointestinal cancer patients may also suffer from the pain of different intensity. Administration of IMRT for a gastric tumour in patients with satisfactory performance status leads to a decrease of symptoms, among others---pain---in more than 70% of patients \[[@B151-cancers-11-00390]\]. Pain may be experienced by advanced rectal cancer patients. Palliative radiation therapy to the pelvis, both using conventional fractionation (45 Gy in 25 fractions) and hypofractionated radiotherapy (30 Gy in 6 fractions) produces satisfactory pain relief in approximately 70% of patients \[[@B152-cancers-11-00390],[@B153-cancers-11-00390]\]. As many as 40% of pancreatic cancer patients are diagnosed with locoregionally advanced disease or progress during the course of the disease \[[@B154-cancers-11-00390]\]. The infiltration of nerves in the area surrounding the pancreas is observed in 43--72% of patients, which causes severe pain \[[@B155-cancers-11-00390]\]. Delivering median 28 Gy (25--33 Gy) in 5 fractions using SBRT resulted in abdominal pain relief in 78% of advanced pancreatic cancer patients \[[@B156-cancers-11-00390]\].

6. Pain Assessment after Radiation Therapy {#sec6-cancers-11-00390}
==========================================

There is no uniform pain assessment in cancer patients receiving radiation therapy. Some authors report pain control as subjective physician/patient reports \[[@B75-cancers-11-00390],[@B76-cancers-11-00390],[@B102-cancers-11-00390],[@B157-cancers-11-00390]\]. Validated Brief Pain Inventory (BPI) was also used \[[@B158-cancers-11-00390]\]. The International Bone Metastases Consensus Working Party proposed pain response categories in palliative radiation therapy \[[@B159-cancers-11-00390]\]. They defined four response categories:Complete response: A pain score of 0 at the treated site and no concomitant increase in analgesic intake, which means stable or reduced analgesics in daily oral morphine equivalent (OMED).Partial response: Pain decrease of 2 or more at the treated site on a scale of 0 to 10 without analgesic increase, or analgesic dose decrease of 25% or more from the baseline without an increase in pain intensity.Pain progression: Increase in pain score of 2 or more above the baseline at the treated site with stable OMED, or an increase of 25% or more OMED in comparison to the baseline with the pain score stable or 1 point above the baseline.Intermediate response: Any response that is not captured by those defined above \[[@B159-cancers-11-00390]\].

7. Future Directions {#sec7-cancers-11-00390}
====================

New and high-quality prospective data is awaited that will answer several questions and allow for definite statements regarding different combinations of radiation therapy (IMRT, SBRT, brachytherapy, and radionuclide therapy) with surgery (kyphoplasty or vertebroplasty for spine metastases or intramedullary fixation or endoprosthetic reconstruction for long bone metastases) and/or novel molecularly targeted agents/immunotherapy. Prospective phase III randomized studies will define the optimal use (in terms of efficacy and toxicity) of SBRT for treatment of newly diagnosed or recurrent painful spinal metastases. The STEREO-OS trial, which assesses the effect of standard systemic treatment in oligometastatic (3--5 sites) prostate, breast, and/or lung cancer patients in combination with SBRT for painful bone metastases \[[@B160-cancers-11-00390]\], may serve as an example. Biological image-guided SBRT for painful bone metastases, with non-homogenous dose escalation based on FDG-PET(^18^F-Fluorodeoxyglucose---positron emission tomography) results, is another interesting concept \[[@B161-cancers-11-00390]\]. Delivering high biological dose in the tumour region using IMRT with integrated boost for painful spinal bone metastases is the subject of the IRON-2 trial (Intensity-modulated Radiotherapy With Integrated-boost in Patients With Spinal Bone Metastases) \[[@B162-cancers-11-00390]\]. Furthermore, the VERTICAL study is ongoing, assessing the analgesic effect of SBRT comparing to standard low dose EBRT \[[@B163-cancers-11-00390]\]. Prospective cohorts of patients with painful bone metastases (the PRESENT study---Prospective Evaluation of Interventional Studies on Bone Metastases) or exclusively with long bone metastases (the OPTIMAL study) are formed to better guide personalized treatment in terms of improved quality of life and analgesic effect of radiation therapy, surgery, or combined treatment modalities \[[@B164-cancers-11-00390],[@B165-cancers-11-00390]\].

A novel concept is a radiosurgical hypophysectomy for intractable bone metastases pain. Australian researchers will assess whether delivery of a single high dose (150 Gy) of radiation therapy to a small area of the pituitary gland and pituitary stalk in a highly precise manner may be helpful in reducing intractable pain from bone metastases \[[@B166-cancers-11-00390]\].

The Palliative Radiotherapy and Inflammation Study (PRAIS) aims to find predictive factors associated with inflammation for palliative RT for cancer-induced pain response \[[@B167-cancers-11-00390]\]. Furthermore, the latest findings over genetic biomarkers of different aspects of palliative RT for painful bone metastases are very interesting. Namely, Furfari et al. \[[@B168-cancers-11-00390],[@B169-cancers-11-00390],[@B170-cancers-11-00390]\] identified genes' profiles for changes in quality of life and pain relief, pain flare, and dexamethasone response following RT.

Development of higher quality data will further help find the best combinations of EBRT with bisphosphonates, radiopharmaceuticals, and novel biological agents reducing formation/activity of osteoclasts and bone resorption, like monoclonal antibody directed against RANKL---Receptor Activator for Nuclear Factor κ B Ligand (e.g., denosumab or novel agents, like JMT103) \[[@B171-cancers-11-00390],[@B172-cancers-11-00390]\] or reducing cancer-induced bone osteolysis c-src inhibitors (dasatinib, bosutinib) \[[@B173-cancers-11-00390]\].

8. Conclusions {#sec8-cancers-11-00390}
==============

Radiation therapy plays an important role in pain relief in cancer patients. As the radiation oncology field evolved, a number of challenges appeared. Important issues exist which have to be resolved, such as the following: Inconsistent endpoints of trials, difficulty in measuring the response, reluctance to practice evidence-based medicine (e.g., the choice of optimal regimen, re-treatment fractionation), differences in physicians' and patients' perspectives, as well as incorporating systemic treatment in combination with radiation therapy (bisphosphonates, nanotechnology, etc.).

Evidence-based treatment guidelines should be established and followed. Collaboration in multidisciplinary tumour boards provides the best, personalized, holistic care, which leads to, among others, pain reduction and an improved quality of patients' life.
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![Simulation fields (pink rectangle) for irradiation of painful bone metastases with megavoltage photon external beams: (**A**) humeral bone, (**B**) spine, (**C**) foot bones.](cancers-11-00390-g001){#cancers-11-00390-f001}

![Isodose distribution in three-dimensional conformal radiation therapy (3D-CRT) for painful metastasis in dorsal vertebra: (**A**) one beam, (**B**) two oblique beams, (**C**) volumetrically modulated arch therapy (VMAT).](cancers-11-00390-g002){#cancers-11-00390-f002}

![Simulation fields (pink rectangle) for irradiation of painful bone metastases with megavoltage photon external beams. (**A**,**B**)---metastases to the femur after surgical stabilization, (**C**)---metastasis to the vertebral body after percutaneous vertebroplasty.](cancers-11-00390-g003){#cancers-11-00390-f003}

![Usage of radioactive isotopes for multiple bone metastases. Abbreviations: ^223^Ra---Radium-223, ^89^Sr---Strontium-89, ^153^Sm---Samarium-153, α---alpha particle, β^−^---beta-minus particle.](cancers-11-00390-g004){#cancers-11-00390-f004}

![Local bone analgesic activity of alpha radiation delivered with Radium-223-dichloride.](cancers-11-00390-g005){#cancers-11-00390-f005}

cancers-11-00390-t001_Table 1

###### 

Factors influencing the radiation technique and fractionation schemes in the treatment of painful bone metastases in clinical practice.

  Patient-Related Factors                                                                                                                                                                                                                                  Tumour-Related Factors                                                                                                                                                          Logistic Issues
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Performance statusPatient's mobilityClinical circumstances painful uncomplicated bone metastasespathologic fracturesspinal cord compressionre-irradiationCompliance to treatmentLife expectancySocioeconomic statusPatient's preferencesPain intensity   Histologic type of primary tumourTime elapsed from primary diagnosis to bone metastasesMultiplicity of metastasesTime of developing pain or neurologic deficits before RT ^1^   Treatment durationSignificance of family members' assistanceHospital locationDistance from patient's home to radiation therapy departmentCost of therapyReimbursement issuesOrganization of radiation departmentsAvailability of multidisciplinary tumour board

^1^ Radiation therapy.

cancers-11-00390-t002_Table 2

###### 

Clinical studies demonstrating the analgesic effect of radiation therapy on painful bone metastases depending on dose and fractionation regimen.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------
  Trial                                                   Number of Patients   Fractionation   Complete or Partial Pain Response   Complete Pain Response
  ------------------------------------------------------- -------------------- --------------- ----------------------------------- ------------------------
  Price et al., 1986 \[[@B29-cancers-11-00390]\]          288                  1 × 8 Gy\       73%\                                45%\
                                                                               10 × 3 Gy       64%                                 28%

  Cole et al., 1989 \[[@B30-cancers-11-00390]\]           29                   1 × 8 Gy\       88%\                                NR ^2^\
                                                                               6 × 4 Gy        85%                                 NR ^2^

  Gaze et al., 1997 \[[@B26-cancers-11-00390]\]           280                  1 × 10 Gy\      84%\                                39%\
                                                                               5 × 4.5 Gy      89%                                 48%

  Nielsen et al., 1998 \[[@B25-cancers-11-00390]\]        241                  1 × 8 Gy\       44%\                                15%\
                                                                               5 × 4 Gy        46%                                 17%

  Steenland et al., 1999 \[[@B24-cancers-11-00390]\]      1171                 1 × 8 Gy\       72%\                                37%\
                                                                               6 × 4 Gy        69%                                 33%

  Koswig et al., 1999 \[[@B17-cancers-11-00390]\]         107                  1 × 8 Gy\       79%\                                31%\
                                                                               10 × 3 Gy       82%                                 33%

  BPTWP ^1^ 1999 \[[@B22-cancers-11-00390]\]              272                  1 × 8 Gy\       72%\                                52%\
                                                                               5 × 4 Gy        68%                                 51%

  Roos 2005 \[[@B31-cancers-11-00390]\]                   275                  1 × 8 Gy\       61%\                                15%\
                                                                               10 × 3 Gy       53%                                 18%

  Hartsell et al., 2005 \[[@B32-cancers-11-00390]\]       998                  1 × 8 Gy\       65%\                                15%\
                                                                               10 × 3 Gy       66%                                 18%

  Foro Arnalot et al., 2008 \[[@B23-cancers-11-00390]\]   160                  1 × 8 Gy\       75%\                                15%\
                                                                               10 × 3 Gy       86%                                 13%

  Nongkynrih et al., 2018 \[[@B27-cancers-11-00390]\]     60                   1 × 8 Gy\       80%\                                20%\
                                                                               5 × 4 Gy\       75%\                                20%\
                                                                               10 × 3 Gy       85%                                 20%
  ---------------------------------------------------------------------------------------------------------------------------------------------------------

^1^ BPTWP---Bone Pain Trial Working Party, ^2^ NR---not reported.

cancers-11-00390-t003_Table 3

###### 

Pain response after re-irradiation of painful spine metastases \[[@B58-cancers-11-00390],[@B73-cancers-11-00390],[@B74-cancers-11-00390],[@B75-cancers-11-00390],[@B76-cancers-11-00390],[@B77-cancers-11-00390]\].

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                                Initial RT Dose (Median)   Re-Irradiation Modality   Re-Treatment Dose                                    Pain Response
  ---------------------------------------------------- -------------------------- ------------------------- ---------------------------------------------------- -----------------------------------
  Choi et al., 2010 \[[@B73-cancers-11-00390]\]        40 Gy (24.2--50.4)         CyberKnife                Median marginal dose 20 Gy/2fr (range 18/1--25/5)\   65% improvement in pain
                                                                                                            30 Gy/5fr                                            

  Garg et al., 2011 \[[@B74-cancers-11-00390]\]        30 Gy (30--45)             IG-IMRT                   27 Gy/3fr\                                           Improvement in pain at 6 months
                                                                                                            20 Gy/5fr                                            

  Damast et al., 2011 \[[@B75-cancers-11-00390]\]      30 Gy (8--66)              IG-IMRT                   20 Gy/5fr\                                           77% improvement in pain
                                                                                                            30 Gy/5fr                                            

  Mahadevan et al., 2011 \[[@B76-cancers-11-00390]\]   30 Gy (8--46)              CyberKnife                25--30 Gy/5fr\                                       79% improvement in pain
                                                                                                            24 Gy/3fr                                            

  Chang et al., 2012 \[[@B58-cancers-11-00390]\]       39Gy Gy~2~ ^1^             CyberKnife                20.6 Gy/1fr (18.2--23.7)                             80.8% pain control rate at 1 year

  Hashmi et al., 2016 \[[@B77-cancers-11-00390]\]      30 Gy/10fr                 IG-IMRT                   16.6 Gy/fr\                                          74.3% improvement in pain
                                                                                                            24 Gy/3fr                                            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^1^ Gy is a way to normalize radiation doses that may have been given in a different dose/fractionation schedule. It converts all doses to the equivalent dose in 2 Gy per fraction. Abbreviations: fr---fraction, RT---radiation therapy, IG-IMRT---image-guided intensity modulated radiation therapy.

cancers-11-00390-t004_Table 4

###### 

Influence of brachytherapy on pain control in painful spine tumours \[[@B83-cancers-11-00390],[@B84-cancers-11-00390],[@B85-cancers-11-00390],[@B86-cancers-11-00390],[@B87-cancers-11-00390],[@B88-cancers-11-00390],[@B89-cancers-11-00390]\]. ^125^I-iodine, 153Sm-samarium, SM---spinal metastases, VAS-visual-analogue scale of pain assessment.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Study                                              Brachytherapy Intervention                                                                 Pain Control\                       
                                                                                                                                                VAS (Mean +/− Standard Deviation)   
  -------------------------------------------------- ------------------------------------------------------------------------------------------ ----------------------------------- ---------------
  Cardoso et al., 2009 \[[@B83-cancers-11-00390]\]   Percutaneous curettage of SM cement augmentation, and bone cement injection with ^153^Sm   8.5 +/− 2                           2.6 +/− 3.1

  Yang et al., 2013 \[[@B84-cancers-11-00390]\]      Cement augmentation and percutaneous ^125^I seed implantation                              8.73 +/− 0.31                       1.32 +/− 0.37

  Cao et al., 2014 \[[@B85-cancers-11-00390]\]       Percutaneous ^125^I seed implantation                                                      4.48 +/− 2.03                       1.18 +/− 1.38

  Huang et al., 2014 \[[@B89-cancers-11-00390]\]     Cement augmentation and percutaneous ^125^I seed implantation                              7.12 +/− 1.48                       2.26 +/− 1.07

  Li et al., 2014 \[[@B86-cancers-11-00390]\]        Cement augmentation and percutaneous ^125^I seed implantation                              7.7 +/− 1.3 (SN)\                   2.6 +/− 1.0\
                                                                                                                                                8.0 +/− 1.2 (MN)                    2.4 +/− 1.1

  Wang et al., 2015 \[[@B87-cancers-11-00390]\]      Cement augmentation and percutaneous ^125^I seed implantation                              6.37 +/− 1.67                       1.32 +/− 0.75

  Qian et al., 2016 \[[@B88-cancers-11-00390]\]      Pedicle fixation of affected vertebra and implantation of ^125^I seeds via needles         7.43 +/− 0.98                       4.29 +/− 0.98
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: ^125^I---iodine, ^153^Sm---samarium, SM---spinal metastases, VAS-visual-analogue scale of pain assessment.
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###### 

Radioactive isotopes used for the treatment of painful bone metastases.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Radioactive Isotope                                           Trial                                                   Study Type      Number of Patients                                                   Cancer                                                      Analgesic Effect     Duration of Analgesic Effect
  ------------------------------------------------------------- ------------------------------------------------------- --------------- -------------------------------------------------------------------- ----------------------------------------------------------- -------------------- ------------------------------
  Radium-223-Chloride                                           Nilsson et al., 2005 \[[@B145-cancers-11-00390]\]       phase I         25 pts                                                               breast, prostate                                            50% pts              1 WP 52%,\
                                                                                                                                                                                                                                                                                              4 WP 60%,\
                                                                                                                                                                                                                                                                                              8 WP 56%

  Bruland et al., 2006 \[[@B146-cancers-11-00390]\]             phase I                                                 6 pts           prostate                                                             repeated administration was well tolerated                  NS                   

  Nilsson et al., 2007 \[[@B147-cancers-11-00390]\]             phase II randomized                                     64 pts          prostate                                                             10 versus 16 (placebo) reported bone pain after injection   NS                   

  Coleman et al., 2014 \[[@B148-cancers-11-00390]\]             phase IIa                                               23 pts          breast                                                               BPI pain severity index at week 17 was 0.6                  NS                   

  Parker et al., 2011 *ALSYMPCA* \[[@B127-cancers-11-00390]\]   phase III randomized                                    921 pts         castration-resistant prostate                                        NS                                                          NS                   

  Prelaj at al., 2019 \[[@B149-cancers-11-00390]\]              retrospective                                           32 pts          prostate                                                             71%                                                         NS                   

  Rhenium-186-HEDP                                              Maxon et al., 1991 \[[@B136-cancers-11-00390]\]         double-blind    20 pts                                                               prostate                                                    80% pts              NS

  Maxon et al., 1992 \[[@B137-cancers-11-00390]\]               prospective                                             43 pts          breast, prostate                                                     77% pts initial injection\                                  7 weeks              
                                                                                                                                                                                                             50% second in injection                                                          

  Han et al., 1999 \[[@B138-cancers-11-00390]\]                 prospective                                             30 pts          breast                                                               58% pts                                                     NS                   

  Han et al., 2002\                                             double-blind randomized                                 111 pts         prostate                                                             0--96% (mean 27%)                                           NS                   
  *PLACORHEN* \[[@B139-cancers-11-00390]\]                                                                                                                                                                                                                                                    

  Rhenium-188-HEDP                                              Palmedo et al., 2000 \[[@B142-cancers-11-00390]\]       prospective     22 pts                                                               prostate                                                    64%                  7.5 weeks

  Liepe et al., 2000 \[[@B143-cancers-11-00390]\]               prospective                                             15 pts          prostate                                                             76%                                                         NS                   

  Samarium-153-EDTMP                                            Dolezal et al., 2000 \[[@B114-cancers-11-00390]\]       prospective     33 pts                                                               prostate, breast, other                                     70%                  NS

  Wang et al., 2003 \[[@B115-cancers-11-00390]\]                Comparative randomized                                  9 pts           prostate, breast, other                                              78%                                                         3.5 +/− 2.3 months   

  Sapienza et al., 2004 \[[@B116-cancers-11-00390]\]            retrospective                                           73 pts          prostate, breast                                                     76%                                                         NS                   

  Samarium-153-EDTMP                                            Etchebehere et al., 2004 \[[@B117-cancers-11-00390]\]   retrospective   58 pts                                                               prostate, breast, other                                     78%                  5.75--6 months

  Sartor et al., 2004 \[[@B118-cancers-11-00390]\]              phase III randomized                                    152 pts         prostate                                                             64%                                                         NS                   

  Tripathi et al., 2006 \[[@B119-cancers-11-00390]\]            prospective                                             86 pts          prostate, breast, other                                              73%                                                         2--8 months          

  Ripamonti et al., 2007 \[[@B120-cancers-11-00390]\]           prospective                                             13 pts          prostate, breast                                                     61,5%                                                       NS                   

  Liepe et al., 2007 \[[@B109-cancers-11-00390]\]               prospective                                             15 pts          prostate, breast                                                     73%                                                         10 +/− 1 weeks       

  Dolezal et al., 2007 \[[@B121-cancers-11-00390]\]             prospective                                             32 pts          prostate                                                             72%                                                         3 months             

  Strontium-89 Dichloride                                       Sciuto. et al., 2001 \[[@B104-cancers-11-00390]\]       randomized      51 pts                                                               breast                                                      84%                  2--14 months

  Turner et al., 2001 \[[@B105-cancers-11-00390]\]              prospective                                             93 pts          prostate                                                             63%                                                         NS                   

  Dafermou et al., 2001 \[[@B106-cancers-11-00390]\]            multicentre observational                               527 pts         prostate                                                             59.8%                                                       5.0 +/− 3.5 months   

  Ashayeri et al., 2002 \[[@B107-cancers-11-00390]\]            prospective                                             27 pts          prostate, breast                                                     81%                                                         up to 1 year         

  Baczyk et al., 2003 \[[@B108-cancers-11-00390]\]              prospective                                             70 pts          prostate                                                             88%                                                         3--12 months         

  Fettich et al., 2003 \[[@B103-cancers-11-00390]\]             prospective                                             93 pts          bone mts                                                             75%                                                         NS                   

  Liepe et al., 2007 \[[@B109-cancers-11-00390]\]               prospective                                             15 pts          prostate, breast                                                     72%                                                         9 +/− 2 weeks        

  Ma et al., 2008 \[[@B94-cancers-11-00390]\]                   prospective                                             116 pts         prostate                                                             83.6%                                                       3--12 months         

  Zenda et al., 2014 \[[@B110-cancers-11-00390]\]               prospective                                             54 pts          26 pts prostate/breast\                                              69.2%\                                                      2--6 months          
                                                                                                                                        28 pts other malignancies (lung, head and neck, colorectal, other)   73.1%                                                                            
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Abbreviations: PTS---patients, NS---not stated, WP---week point, BPI---Brief Pain Inventory, MTS---metastases.
